Lanzostad (Lansoprazole)

Lansoprazole blocks the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells in the stomach. By irreversibly inhibiting this pump, it prevents the final step of acid production, leading to a sustained increase in gastric pH and allowing ulcerated or inflamed tissue to recover.

The specific dose of Lanzostad is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage forms and strengths are selected according to approved labeling, and the prescriber will provide individualized instructions for each patient.

Safety data for lansoprazole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate the individual situation and advise whether treatment is appropriate during pregnancy or while nursing.

To place an order, submit an enquiry on the Lanzostad product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lanzostad (lansoprazole) belongs to the proton pump inhibitor class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, lansoprazole has a similar efficacy profile but may differ slightly in metabolism and drug‑interaction potential, making individual patient factors important in selection.

Lanzostad should be stored at room temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Lanzostad is taken orally, usually with a glass of water. It can be taken with or without food, but consistent timing each day helps maintain steady acid suppression. Patients should follow the prescribing clinician’s instructions regarding the exact timing and any special administration considerations.

Serious risks, though uncommon, include Clostridioides difficile‑associated diarrhea, severe allergic reactions such as anaphylaxis, low magnesium levels with prolonged use, increased risk of bone fractures, interstitial nephritis and liver enzyme abnormalities. Patients should report any severe or unexpected symptoms to their healthcare provider promptly.

Lanzostad is contraindicated in patients with known hypersensitivity to lansoprazole or any component of the formulation. Caution is advised for individuals with severe liver disease, those taking medications that have major interactions, and patients with a history of osteoporosis or fractures when long‑term therapy is considered.